Relaxin H3 (human)

Relaxin H3 (human) 是一种兼具抗炎、抗凋亡、抗焦亡、抗迁移、保护及抗纤维化活性的松弛素肽,它通过作用于 RXFP1 生成 cAMP 并降低 ATP 和 ROS 水平,同时抑制肾脏炎性焦亡 (pyroptosis)、NLRP3 炎症小体激活、caspase-1 激活、IL-1β/IL-18 分泌、胶原蛋白合成、TGF-β1 信号通路、Smad2 磷酸化、肌成纤维细胞分化、TIMP 表达以及 HRMEC 迁移,并可激活 AMPK、上调 MFN2 表达、改善线粒体质量控制与膜电位、抑制凋亡 (apoptosis) 和焦亡、恢复视网膜超微结构并逆转左心室胶原蛋白过度表达,因此可用于肾结石、肾钙质沉着症、糖尿病心肌病、纤维化心肌病及糖尿病视网膜病变的相关研究。
产品编号: MS-C96769 CAS No.: 1158181-62-4 分子式: C237H374N70O69S6 分子量: 5500.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Relaxin H3 (human) 是一种兼具抗炎、抗凋亡、抗焦亡、抗迁移、保护及抗纤维化活性的松弛素肽,它通过作用于 RXFP1 生成 cAMP 并降低 ATP 和 ROS 水平,同时抑制肾脏炎性焦亡 (pyroptosis)、NLRP3 炎症小体激活、caspase-1 激活、IL-1β/IL-18 分泌、胶原蛋白合成、TGF-β1 信号通路、Smad2 磷酸化、肌成纤维细胞分化、TIMP 表达以及 HRMEC 迁移,并可激活 AMPK、上调 MFN2 表达、改善线粒体质量控制与膜电位、抑制凋亡 (apoptosis) 和焦亡、恢复视网膜超微结构并逆转左心室胶原蛋白过度表达,因此可用于肾结石、肾钙质沉着症、糖尿病心肌病、纤维化心肌病及糖尿病视网膜病变的相关研究。

生物实验数据

生物活性 Relaxin H3 (human) is a relaxin peptide possessing anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective, and anti-fibrotic activities; it acts on RXFP1 to generate cAMP and reduce ATP and ROS levels, inhibits renal inflammatory pyroptosis, NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration, and activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, suppresses apoptosis and pyroptosis, restores retinal ultrastructure, and reverses left ventricular collagen overexpression, making it suitable for research on kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
IC50 & Target

Caspase-1

 

IL-1β

 

IL-18

 

体外研究
(In Vitro)

Relaxin H3 (human) (20 ng/mL; 2 h pretreatment) 可通过 RXFP1-cAMP 通路减少 ROS 生成、降低 ATP 水平并抑制 NLRP3 炎症小体-GSDMD 轴的激活,从而保护人近端肾小管 HK2 细胞免受 Ca2+Ox 晶体诱导的细胞焦亡与炎症损伤。
Relaxin H3 (human) (20 ng/mL; 2 h pretreatment) 可减少 Ca2+Ox 晶体对人近端肾小管 HK2 细胞的黏附与内化作用,并抵消 Ca2+Ox 诱导的培养基酸化。
Relaxin H3 (human) (100 ng/mL; 30 min pre-incubation, 48 h exposure/treatment) 可抑制高糖诱导的新生大鼠心脏成纤维细胞中胶原蛋白合成、NLRP3 炎症小体活化、ROS 生成及 P2X7R 表达。
Relaxin H3 (human) (10-500 ng/mL; 72 h) 可在 100 ng/mL 和 250 ng/mL 浓度下作用 72 h,强效抑制 TGF-β1 刺激的原代新生大鼠心室成纤维细胞的胶原沉积。
Relaxin H3 (human) (100 ng/mL; 72 h) 可抑制转化生长因子-β1 (TGF-β1) 诱导的 Smad2 磷酸化达 40%,并能完全抑制 TGF-β1 诱导的原代新生大鼠心室成纤维细胞向肌成纤维细胞分化 (α-SMA 表达)。
Relaxin H3 (human) (100 ng/mL; 72 h) 在转化生长因子-β1 (TGF-β1) 刺激的原代新生大鼠心室成纤维细胞中可显著抑制 TIMP-1 和 TIMP-2 的表达,抑制率达 50%-55%。
Relaxin H3 (human) (100 ng/mL; 30 min pre-incubation then 48 h, or 48 h) 可通过抑制 P2X7R 介导的信号通路,减轻 AGE-BSA 诱导的人视网膜微血管内皮细胞中 NLRP3 炎症小体激活、细胞凋亡、细胞焦亡及细胞迁移。
Relaxin H3 (human) (100 ng/mL) 可通过调控凋亡相关蛋白、线粒体融合/分裂/线粒体自噬蛋白、ROS 水平、膜电位及 ATP 生成,提高 H9C2 大鼠心肌细胞的活力、减少细胞凋亡,并改善高糖和棕榈酸诱导的线粒体功能障碍。
Relaxin H3 (human) (100 ng/mL) 可通过逆转凋亡及线粒体质量控制蛋白的异常表达、减少 ROS、恢复膜电位并提升 ATP 水平,缓解高糖和棕榈酸诱导的 MFN2 敲低 H9C2 大鼠心肌细胞的凋亡及线粒体功能障碍。
Relaxin H3 (human) (100 ng/mL) 可通过激活 AMPK 通路,对高糖和棕榈酸诱导的 H9C2 大鼠心肌细胞凋亡及线粒体功能障碍发挥保护作用。

体内研究
(In Vivo)

Relaxin H3 (human) (0.2-2 μg/kg/d;皮下注射;每日给药;7 或 14 天) 保护雄性 Sprague-Dawley 大鼠免受草酸肾病损伤,其通过 RXFP1-cAMP 轴抑制 P2X7R-ROS-NLRP3 炎性体通路,从而减少肾脏细胞焦亡、晶体沉积及肾功能损伤。
Relaxin H3 (human) (0.5 mg kg/day;皮下注射;持续输注;14 天) 可使 β2-AR 转基因小鼠中已形成的心肌纤维化逆转 50%。
Relaxin H3 (human) (0.2-2 µg/kg/d;每日给药;连续 14 天) 可呈剂量依赖性地改善 Streptozotocin (MS-Q80520) 诱导的糖尿病大鼠的视网膜超微结构,减轻 NLRP3 炎症小体介导的炎症反应,并抑制细胞凋亡,且 2 µg/kg/d 剂量的保护作用强于 0.2 µg/kg/d 剂量。
Relaxin H3 (human) (2 μg/kg/d;腹腔注射;每日给药;持续 2 周) 可通过激活 AMPK 通路改善糖尿病心肌病 Sprague-Dawley 大鼠的代谢紊乱、心脏结构与功能、线粒体质量控制,并减少心肌细胞凋亡,同时显著降低 LVIDd、LVIDs、促凋亡蛋白及分裂/线粒体自噬蛋白水平。

Animal Model: Sprague-Dawley (male, 5-6 weeks old, 150-200 g, oxalate nephropathy induced by 0.8% ethylene glycol and 0.8% NH4Cl in drinking water)
Dosage: 0.2 μg/kg/d; 2 μg/kg/d
Administration: s.c.; daily; 7 or 14 days
Result: Reduced renal tissue ATP levels in a dose-dependent manner after 7 and 14 days compared to the EG model group.
Reduced serum creatinine and blood urea nitrogen levels in a dose-dependent manner after 14 days compared to the EG model group.
Improved tubular dilatation, neutrophil infiltration, and epithelial cell deformation/exfoliation in a dose-dependent manner compared to the EG model group (histological analysis).
Reduced levels of cleaved caspase-1, GSDMD, and NLRP3 in renal tissues compared to the EG model group (immunohistochemical assays).
Reduced CaOx crystal deposition, hydronephrosis, and renal cortex thinning compared to the EG model group (ultrasonographic examination).
Reduced renal crystal deposition in a dose-dependent manner compared to the EG model group (Von Kossa staining).
Reduced levels of NLRP3, ASC, cleaved caspase-1, cleaved GSDMD, IL-18, and IL-1β in renal tissues compared to the EG model group (Western blot analysis).
Animal Model: C57Blk6JxSJL background (4-5-month-old male, heterozygous β2-adrenergic receptor, cardiac fibrosis induced by cardiac-restricted transgenic overexpression of β2-AR)
Dosage: 0.5 mg kg-1 day-1
Administration: s.c.; continuous infusion; 14 days
Result: Reversed established left ventricular collagen accumulation by 50%.
Animal Model: Sprague-Dawley (SD) (male, 200-250 g, STZ-induced diabetes)
Dosage: 0.2 µg/kg/d; 2 µg/kg/d
Administration: daily; 14 days
Result: Reduced retinal expression of NLRP3 inflammasome-related proteins (NLRP3, ASC, cleaved caspase-1, IL-18, IL-1β) and apoptosis-related proteins (cleaved caspase-3, cleaved caspase-8, cleaved caspase-9) compared to untreated diabetic rats, with high-dose showing greater reduction at both 4 and 8 weeks.
Decreased plasma levels of VEGF, TNF-α, IL-18, and IL-1β, with high-dose treatment leading to significantly lower levels.
Improved retinal ultrastructure at 8 weeks, with high-dose treatment resulting in substantially clearer retinal membrane discs, increased synapse numbers in the outer and inner plexiform layers, and normal ganglion cell morphology; improvement was less pronounced in the low-dose group.
Animal Model: Sprague-Dawley rats (male/female not specified; induced via high-fat diet plus intraperitoneal streptozotocin injection, fasting blood glucose ≥16.7 mmol/L)
Dosage: 2 μg/kg/d
Administration: i.p.; daily; 2 weeks
Result: Improved glucose tolerance and insulin sensitivity.
Reduced serum total cholesterol, triglyceride, and insulin levels.
Ameliorated disorganized myocardial cells, edema, fibrosis, and collagen deposition.
Restored damaged mitochondrial ultrastructure.
Reduced left ventricular internal diameter at end-diastole (LVIDd) from 8.17 mm to 7.46 mm and left ventricular internal diameter at end-systole (LVIDs) from 5.53 mm to 4.95 mm.
Improved left ventricular ejection fraction.
Upregulated anti-apoptotic protein BCL-2 and downregulated pro-apoptotic proteins BAX and cleaved caspase-3.
Increased mitochondrial fusion proteins MFN2 and OPA1.
Reduced mitochondrial fission proteins Drp1 and Fis1.
Decreased mitophagy proteins parkin and PINK1.
Increased p-AMPK/AMPK ratio.
All changes were statistically significant compared to the diabetic cardiomyopathy group.

化学信息

分子量 5500.32
分子式 C237H374N70O69S6
CAS No. 1158181-62-4

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础